Emisphere Technologies (EMIS) Stock Research, Analysis & News

Quick Analysis on Emisphere Technologies (EMIS) Stock as of August 22, 2017

Previous Closing Price $0.33 is below its 50 day moving average $0.39
Previous Closing Price $0.33 is below its 200 day moving average $0.45
The Stock pays no dividend
The closing price $0.33 is more than 127.27% away from its one year target price of $0.75
Current Short Ratio 1.65 is great than 1
Next year EPS Estimate of $N/A is lower than curreny year EPS Estimate $nan
Earning per Share $-0.10 is negative. Emisphere Technologies is lossing money.
EBITDA $-6.21M is negative
Average trading volume is relatively low at 31,347
It is a very small cap stock with market cap of $21.30M
(See more information about Emisphere Technologies (EMIS) Stock below)

Emisphere Technologies (EMIS) Stock Profile Summary

Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its eligen technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The companys product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the companys product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc. The company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey.

Emisphere Technologies (EMIS) Stock Key Statistics Research and Analysis as of August 22, 2017

Stock ExchangePNK
Market Capitalization$21.30M
Trade Volume (Average Trading Volume)37,390 (31,347)
Price/Sales19.22
Earning/Share$-0.10
Previous Closing Price$0.33
50 Day Price Moving Average$0.39
200 Day Price Moving Average$0.45
1 yr Target Price$0.75
PEG Ratio0.00
Short Ratio1.65
EBITDA$-6.21M

Latest Market News on Emisphere Technologies (EMIS)


Click here to find the latest news on Emisphere Technologies (EMIS)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center